EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis

Maiara Jochims Fumagalli, Karen Cherubini, Juliana Cassol Spanemberg, Fernanda Gonçalves Salum

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · 2025

DOI: 10.1016/j.oooo.2024.12.002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2025. Verfasst von Maiara Jochims Fumagalli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil. Hauptthemen laut MEDLINE: Cheilitis, Aminoquinolines, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.125 mg/g creams in the treatment of AC. STUDY DESIGN: A randomized controlled trial was conducted. Twenty-five participants of both genders, with a clinical diagnosis of AC, were divided into IM (n=13) and FC (n=12) groups. The treatment duration was six weeks for both groups. Participants were followed up by regular visits for clinical examination and photographic documentation. RESULTS: At the end of 180 days, the clinical outcomes were evaluated. In the IM group, there was a significant improvement in AC after 180 days of follow-up (P = .005). In the FC group, there was no significant improvement (P = .317). There was a significant difference between the groups in the clinical outcomes (P = .000). CONCLUSION: This study suggests that imiquimod may be a treatment option for AC in more advanced clinical cases, but local reactions should be expected. Conversely, fludroxycortide demonstrated no clinical efficacy, and therefore, should be avoided in AC cases presenting with leukoplakia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CheilitisAminoquinolinesAntineoplastic AgentsHumansImiquimodFemaleMaleMiddle AgedTreatment OutcomeAgedAdult

Substanzen

ImiquimodAminoquinolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil.
  • Faculty of Health Sciences, Department of Dentistry, Fernando Pessoa Canarias University, Spain.
  • Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil. Electronic address: fernanda.salum@pucrs.br.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Fumagalli, M. J., Cherubini, K., Spanemberg, J. C., & Salum, F. G. (2025). Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. https://doi.org/10.1016/j.oooo.2024.12.002

Vancouver

Fumagalli MJ, Cherubini K, Spanemberg JC, Salum FG. Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2025. doi:10.1016/j.oooo.2024.12.002

BibTeX
@article{Fumagalli2025,
  author = {Fumagalli, Maiara Jochims and Cherubini, Karen and Spanemberg, Juliana Cassol and Salum, Fernanda Gonçalves},
  title = {Randomized clinical trial of imiquimod compared with fludroxycortide in the treatment of actinic cheilitis},
  journal = {Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology},
  year = {2025},
  doi = {10.1016/j.oooo.2024.12.002}
}
Kostenlos starten →